These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 36136207)

  • 21. Comparison of the mathematical equation and trapezoidal approach for 24 h area under the plasma concentration-time curve calculation in patients who received intravenous vancomycin in an acute care setting.
    Chanapiwat P; Paiboonvong T; Rattanaumpawan P; Montakantikul P
    Pharmacol Res Perspect; 2023 Feb; 11(1):e01046. PubMed ID: 36588162
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Area-Under-Curve-Guided Versus Trough-Guided Monitoring of Vancomycin and Its Impact on Nephrotoxicity: A Systematic Review and Meta-Analysis.
    Lim AS; Foo SHW; Benjamin Seng JJ; Magdeline Ng TT; Chng HT; Han Z
    Ther Drug Monit; 2023 Aug; 45(4):519-532. PubMed ID: 36728329
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimizing outcomes using vancomycin therapeutic drug monitoring in patients with MRSA bacteremia: trough concentrations or area under the curve?
    Johnston MM; Huang V; Hall ST; Buckley MS; Bikin D; Barletta JF
    Diagn Microbiol Infect Dis; 2021 Oct; 101(2):115442. PubMed ID: 34192639
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduced nephrotoxicity with vancomycin therapeutic drug monitoring guided by area under the concentration-time curve against a trough 15-20 μg/mL concentration.
    Oda K; Jono H; Nosaka K; Saito H
    Int J Antimicrob Agents; 2020 Oct; 56(4):106109. PubMed ID: 32721597
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Balancing vancomycin efficacy and nephrotoxicity: should we be aiming for trough or AUC/MIC?
    Patel K; Crumby AS; Maples HD
    Paediatr Drugs; 2015 Apr; 17(2):97-103. PubMed ID: 25644329
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trough-guided Versus AUC/MIC-Guided Vancomycin Monitoring: A Cost Analysis.
    Morales Junior R; Tiguman GMB; D'Amaro Juodinis V; Santos ICPF; Leite FS; Vercelino JG; de Lima BD; Barbosa LMG
    Clin Ther; 2022 Sep; 44(9):e91-e96. PubMed ID: 36031477
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes of a pharmacist-driven vancomycin monitoring initiative in a community hospital.
    Joseph K; Ramireddy K; Madison G; Turco T; Lui M
    J Clin Pharm Ther; 2021 Aug; 46(4):1103-1108. PubMed ID: 33768555
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Coagulase negative staphylococcal sepsis in neonates: do we need to adapt vancomycin dose or target?
    Padari H; Oselin K; Tasa T; Metsvaht T; Lõivukene K; Lutsar I
    BMC Pediatr; 2016 Dec; 16(1):206. PubMed ID: 27931193
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship between nephrotoxicity and area under the concentration-time curve of vancomycin in critically ill patients: a multicenter retrospective study.
    Ishigo T; Matsumoto K; Yoshida H; Tanaka H; Ibe Y; Fujii S; Fukudo M; Fujihara H; Yamaguchi F; Ebihara F; Maruyama T; Hamada Y; Samura M; Nagumoi F; Komatsu T; Tomizawa A; Takuma A; Chiba H; Nishi Y; Enoki Y; Taguchi K; Suzuki A
    Microbiol Spectr; 2024 Jul; 12(7):e0373923. PubMed ID: 38775483
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of Vancomycin AUC/MIC and Trough Concentration With Early Clinical Response in Enterococcus or Coagulase-Negative Staphylococcus Infection: A Prospective Study.
    Pitayakittiwong C; Sermsappasuk P; Meesing A; Jaisue S
    J Clin Pharmacol; 2024 Aug; 64(8):1006-1014. PubMed ID: 38639115
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correlation of a Vancomycin Pharmacokinetic Model and Trough Serum Concentrations in Pediatric Patients.
    Ploessl C; White C; Manasco K
    Pediatr Infect Dis J; 2015 Oct; 34(10):e244-7. PubMed ID: 26121203
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vancomycin area under the curve/minimum inhibitory concentration and trough level concordance-evaluation on an urban health unit.
    Chen M; Lee C; Gnyra M; Wong M
    Ther Adv Infect Dis; 2022; 9():20499361221140368. PubMed ID: 36465428
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.
    Rybak MJ; Lomaestro BM; Rotschafer JC; Moellering RC; Craig WA; Billeter M; Dalovisio JR; Levine DP
    Pharmacotherapy; 2009 Nov; 29(11):1275-9. PubMed ID: 19873687
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is peak concentration needed in therapeutic drug monitoring of vancomycin? A pharmacokinetic-pharmacodynamic analysis in patients with methicillin-resistant staphylococcus aureus pneumonia.
    Suzuki Y; Kawasaki K; Sato Y; Tokimatsu I; Itoh H; Hiramatsu K; Takeyama M; Kadota J
    Chemotherapy; 2012; 58(4):308-12. PubMed ID: 23147106
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of initial vancomycin pharmacokinetic/pharmacodynamic parameters on the clinical and microbiological outcomes of methicillin-resistant Staphylococcus aureus bacteremia in children.
    Yoo R; So H; Seo E; Kim M; Lee J
    PLoS One; 2021; 16(4):e0247714. PubMed ID: 33793589
    [TBL] [Abstract][Full Text] [Related]  

  • 36. First-Dose Vancomycin Pharmacokinetics Versus Empiric Dosing on Area-Under-the-Curve Target Attainment in Critically Ill Patients.
    Flannery AH; Delozier NL; Effoe SA; Wallace KL; Cook AM; Burgess DS
    Pharmacotherapy; 2020 Dec; 40(12):1210-1218. PubMed ID: 33176005
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimizing Vancomycin Use Through 2-Point AUC-Based Therapeutic Drug Monitoring in Pediatric Patients.
    Suchartlikitwong P; Anugulruengkitt S; Wacharachaisurapol N; Jantarabenjakul W; Sophonphan J; Theerawit T; Chatsuwan T; Wattanavijitkul T; Puthanakit T
    J Clin Pharmacol; 2019 Dec; 59(12):1597-1605. PubMed ID: 31342543
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Attention to age: similar dosing regimens lead to different vancomycin levels among older and younger patients.
    Yahav D; Abbas M; Nassar L; Ghrayeb A; Shepshelovich D; Kurnik D; Leibovici L; Paul M
    Age Ageing; 2019 Dec; 49(1):26-31. PubMed ID: 31711101
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Therapeutic monitoring of vancomycin in routine clinical practice].
    Kacířová I; Grundmann M
    Vnitr Lek; 2014 Oct; 60(10):846-51. PubMed ID: 25382007
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Desired vancomycin trough serum concentration for treating invasive methicillin-resistant Staphylococcal infections.
    Frymoyer A; Guglielmo BJ; Hersh AL
    Pediatr Infect Dis J; 2013 Oct; 32(10):1077-9. PubMed ID: 23652479
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.